2026 Insurance Coverage and Processing Vaccines 
Pharmaceutical Technology
JULY 14, 2025
How will RFK Jr’s American dream for vaccines play out? Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. A decision by the FDA is expected in H1 2026.
Pharmaceutical Technology
JULY 9, 2025
How will RFK Jr’s American dream for vaccines play out? The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 14, 2025
How will RFK Jr’s American dream for vaccines play out? The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.”
Pharmaceutical Technology
JULY 30, 2025
Robert Barrie July 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Prasad, an oncologist who was a fierce critic of the Covid-19 vaccine response in the US, was appointed only three months ago. Prasad, an oncologist who was a fierce critic of the Covid-19 vaccine response in the US, was appointed only three months ago.
Pharmaceutical Technology
JULY 17, 2025
How will RFK Jr’s American dream for vaccines play out? Sarepta Therapeutics is set to cut 500 jobs as part of its restructuring and pipeline prioritisation plan, which is expected to result in annual cash cost savings of $120m in 2026. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Technology
JUNE 13, 2025
Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. Until now, the vaccine was licensed for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older.
Express Pharma
JANUARY 12, 2024
Initiatives such as Ayushmaan Bharat Digital Mission (“ADBDM”), CoWIN (a digital vaccine delivery platform), health registry, and telemedicine, highlight the government’s strong emphasis on digitisation of health in India. Expectation #4 Clarification on product samples and low brand value items – According to CBDT circular no.
Expert insights. Personalized for you.
Let's personalize your content